Renalytix Plc
RNLX · NASDAQ
6/30/2024 | 6/30/2023 | 6/30/2022 | 6/30/2021 | |
|---|---|---|---|---|
| Revenue | $2,289 | $3,403 | $2,970 | $1,491 |
| % Growth | -32.7% | 14.6% | 99.2% | – |
| Cost of Goods Sold | $2,133 | $2,702 | $2,052 | $804 |
| Gross Profit | $156 | $701 | $918 | $687 |
| % Margin | 6.8% | 20.6% | 30.9% | 46.1% |
| R&D Expenses | $9,290 | $14,298 | $14,648 | $10,040 |
| G&A Expenses | $19,751 | $43,056 | $12,951 | $8,374 |
| SG&A Expenses | $19,751 | $43,056 | $12,951 | $8,374 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $656 | $30,691 | $14,884 |
| Operating Expenses | $29,041 | $43,056 | $58,290 | $33,298 |
| Operating Income | -$29,608 | -$42,355 | -$57,372 | -$32,611 |
| % Margin | -1,293.5% | -1,244.6% | -1,931.7% | -2,187.2% |
| Other Income/Exp. Net | -$3,844 | -$3,384 | $12,121 | -$2,114 |
| Pre-Tax Income | -$33,452 | -$46,221 | -$45,251 | -$35,788 |
| Tax Expense | $4 | $2 | $25 | $0 |
| Net Income | -$33,456 | -$45,607 | -$45,276 | -$34,725 |
| % Margin | -1,461.6% | -1,340.2% | -1,524.4% | -2,329% |
| EPS | -0.62 | -1.1 | -1.24 | -0.98 |
| % Growth | 43.6% | 11.3% | -26.5% | – |
| EPS Diluted | -0.62 | -1.1 | -1.34 | -0.98 |
| Weighted Avg Shares Out | 54,090 | 41,105 | 33,991 | 35,434 |
| Weighted Avg Shares Out Dil | 54,090 | 41,105 | 36,919 | 35,742 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $509 | $12 | $236 |
| Interest Expense | $0 | $0 | $2 | $3 |
| Depreciation & Amortization | $364 | $508 | $489 | $282 |
| EBITDA | -$28,521 | -$41,713 | -$52,694 | -$35,503 |
| % Margin | -1,246% | -1,225.8% | -1,774.2% | -2,381.2% |